1. Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, or adult central nervous system (CNS) cancer.
2. Assess relevant pharmacogenomic considerations related to anticancer agents used to treat head, neck, or CNS cancer.
3. Select relevant information and provide guidance to the public regarding head and neck -related issues (e.g., risk factors, prevention, screening).
4. Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cachexia, mucositis, and xerostomia.